首页> 外文期刊>Trials >An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial
【24h】

An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial

机译:一个决策援助的RCT,支持有关服用阿司匹林预防结肠直肠癌和其他慢性病的明智选择:SITA的研究方案(我应该服用阿司匹林吗?)试验

获取原文
       

摘要

Australian guidelines recommend that all people aged 50–70?years old actively consider taking daily low-dose aspirin (100–300?mg per day) for 2.5 to 5?years to reduce their risk of colorectal cancer (CRC). Despite the change of national CRC prevention guidelines, there has been no active implementation of the guidelines into clinical practice. We aim to test the efficacy of a health consultation and decision aid, using a novel expected frequency tree (EFT) to present the benefits and harms of low dose aspirin prior to a general practice consultation with patients aged 50–70?years, on informed decision-making and uptake of aspirin. Approximately five to seven general practices in Victoria, Australia, will be recruited to participate. Patients 50–70?years old, attending an appointment with their general practitioner (GP) for any reason, will be invited to participate in the trial. Two hundred fifty-eight eligible participants will be randomly allocated 1:1 to intervention or active control arms using a computer-generated allocation sequence stratified by general practice, sex, and mode of trial delivery (face-to-face or teletrial). There are two co-primary outcomes: informed decision-making at 1-month post randomisation, measured by the Multi-dimensional Measure of Informed Choice (MMIC), and self-reported daily use of aspirin at 6 months. Secondary outcomes include decisional conflict at 1-month and other behavioural changes to reduce CRC risk at both time points. This trial will test the efficacy of novel methods for implementing national guidelines to support informed decision-making about taking aspirin in 50–70-year-olds to reduce the risk of CRC and other chronic diseases. The Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12620001003965 .?Registered on 10 October 2020.
机译:澳大利亚指南建议所有50-70岁的人?岁月的积极考虑每天服用低剂量阿司匹林(每天100-300毫克)2.5至5岁,以降低整体癌症(CRC)的风险。尽管国家CRC预防指导方针发生了变化,但没有积极执行临床实践指南。我们的目标是使用新的预期频率树(EFT)来测试健康咨询和决策援助的疗效,以在通用实践咨询之前呈现低剂量阿司匹林在与50-70岁的患者(年龄)的咨询之前的益处和危害阿司匹林的决策和吸收。澳大利亚维多利亚大约五到七个一般做法将被招募参加。患者50-70岁?岁月以任何原因与其全科医生(GP)一起学会,将被邀请参加审判。使用一般实践,性别和试用模式(面对面或远程)分层分层的计算机生成的分配序列,将随机分配1:1的干预或主动控制臂。有两种共同原产地结果:在1个月后的随机后明智的决策,通过知情选择(MMIC)的多维测量来衡量,并在6个月内自我报告的日常使用阿司匹林。二次结果包括1个月和其他行为变化的决策冲突,以减少两个时间点的CRC风险。该试验将对实施国家准则的新方法,以支持在50-70岁时服用阿司匹林的知情决策,以降低CRC和其他慢性疾病的风险。澳大利亚新西兰临床试验登记册(ANZCTR)ACTRN12620001003965。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号